Gibson Oncology has begun a phase II trial with LMP744 in recurrent glioblastoma.

This phase II trial is being conducted by the NIH which has done multiple phase 1 studies previously.

LMP744

– Has c-Myc and Topo 1 activity
– Crosses the blood brain-barrier (BBB)
– Has strong PDX data in GBM
– Has FDA Orphan Drug Status

Trial will be in 40 patients who failed initial drug

PRIMARY END POINT

– Tumor regression

SECONDARY END POINT

– Progressive Free Survival (PFS)

-Overall Survival (OS)

The FDA has said that depending on results, this trial may qualify as a Registration Trial.